Stockscreener 앱 받기
42.26
3.67%
-1.61
시간 외 거래:
42.26
전일 마감가:
$43.87
열려 있는:
$43.65
하루 거래량:
594.01K
Relative Volume:
0.69
시가총액:
$3.02B
수익:
$58.89M
순이익/손실:
$-240.88M
주가수익비율:
-13.63
EPS:
-3.1
순현금흐름:
$-239.96M
1주 성능:
-0.21%
1개월 성능:
-7.71%
6개월 성능:
+39.70%
1년 성능:
-13.65%
1일 변동 폭
$41.20
$44.27
1주일 범위
$41.20
$44.50
52주 변동 폭
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
42.26 | 3.14B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Using portfolio simulators with Kymera Therapeutics Inc. includedWeekly Gains Summary & Weekly Watchlist for Consistent Profits - Newser
Is Kymera Therapeutics Inc. stock poised for growthInsider Buying & Daily Stock Trend Watchlist - Newser
Can Kymera Therapeutics Inc. rally from current levelsEarnings Recap Summary & Smart Money Movement Alerts - Newser
Long term hold vs stop loss in Kymera Therapeutics Inc.2025 Momentum Check & Daily Stock Momentum Reports - Newser
News impact scoring models applied to Kymera Therapeutics Inc.2025 Key Highlights & High Conviction Investment Ideas - Newser
What analysts say about Kymera Therapeutics Inc. stock outlookPortfolio Risk Report & Reliable Entry Point Alerts - Newser
Will Kymera Therapeutics Inc. Benefit From Sector TailwindsJuly 2025 Pullbacks & Advanced Technical Analysis Signals - beatles.ru
Real time breakdown of Kymera Therapeutics Inc. stock performance2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Will Kymera Therapeutics Inc. continue its uptrendQuarterly Trade Report & Precise Trade Entry Recommendations - Newser
Can machine learning forecast Kymera Therapeutics Inc. recovery2025 Risk Factors & Growth-Oriented Investment Plans - Newser
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Kymera Therapeutics to Participate in Fireside Chats at Upcoming Investor Events. - AInvest
Clinical-Stage Biotech Kymera Therapeutics Set for 4 Major Investor Conferences Including Morgan Stanley - Stock Titan
Visual trend scoring systems applied to Kymera Therapeutics Inc.Earnings Recap Report & Expert Approved Momentum Trade Ideas - Newser
How to escape a deep drawdown in Kymera Therapeutics Inc.Earnings Overview Report & Precise Trade Entry Recommendations - Newser
Using data models to predict Kymera Therapeutics Inc. stock movementMarket Activity Recap & Verified Swing Trading Watchlists - Newser
Is Kymera Therapeutics Inc. stock ready for a breakoutQuarterly Earnings Report & Risk Controlled Daily Plans - Newser
Historical volatility pattern of Kymera Therapeutics Inc. visualized2025 Key Lessons & Fast Gain Stock Tips - Newser
What Fibonacci levels say about Kymera Therapeutics Inc. rebound2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
Quantitative breakdown of Kymera Therapeutics Inc. recent move2025 Technical Overview & Smart Investment Allocation Tips - Newser
Smart tools for monitoring Kymera Therapeutics Inc.’s price actionRecession Risk & Community Consensus Trade Signals - Newser
Comparing Kymera Therapeutics Inc. in custom built stock radarsWeekly Market Summary & Safe Capital Allocation Plans - Newser
What’s next for Kymera Therapeutics Inc. stock priceEarnings Overview Summary & Low Risk High Reward Ideas - Newser
Published on: 2025-08-26 02:35:34 - theviewers.co.kr
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN
Custom watchlist performance reports with Kymera Therapeutics Inc.2025 Key Lessons & Fast Exit and Entry Trade Guides - Newser
Can Kymera Therapeutics Inc. recover in the next quarter2025 Short Interest & Stepwise Entry/Exit Trade Alerts - Newser
Is This a Bottoming Phase for Kymera Therapeutics Inc.GDP Growth & High Return Trade Opportunity Guides - beatles.ru
Should I hold or sell Kymera Therapeutics Inc. now2025 Trade Ideas & Weekly Sector Rotation Insights - theviewers.co.kr
Measuring Kymera Therapeutics Inc.’s beta against major indicesMarket Activity Report & Fast Moving Trade Plans - Newser
What institutional flow reveals about Kymera Therapeutics Inc.2025 Bull vs Bear & Consistent Income Trade Recommendations - Newser
Is Kymera Therapeutics Inc. a strong candidate for buy and holdJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - theviewers.co.kr
Is Kymera Therapeutics Inc. the Top Chart Pick This WeekQuarterly Market Review & Free Risk Controlled Daily Trade Plans - 더경남뉴스
Support Test: Will Kymera Therapeutics Inc. stock recover after earningsInsider Selling & Daily Profit Focused Screening - theviewers.co.kr
Is Kymera Therapeutics Inc. a play on infrastructure spending2025 Pullback Review & Long-Term Growth Portfolio Plans - theviewers.co.kr
Trendlines Suggest Kymera Therapeutics Inc. May Bottom Out SoonJuly 2025 Levels & Fast Exit Strategy with Risk Control - beatles.ru
Kymera Therapeutics Inc. Stock Poised for Technical ComebackQuarterly Trade Report & Accurate Trade Setup Notifications - 더경남뉴스
Kymera Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Order flow analysis tools used on Kymera Therapeutics Inc.Layoff News & Free Community Supported Trade Ideas - Newser
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
8.06%
자본화:
|
볼륨(24시간):